Literature DB >> 26331999

Management of Benign Prostatic Hyperplasia.

Eric H Kim1, Jeffrey A Larson1, Gerald L Andriole1.   

Abstract

Benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS) commonly affect older men. Age-related changes associated with metabolic disturbances, changes in hormone balance, and chronic inflammation may cause BPH development. The diagnosis of BPH hinges on a thorough medical history and focused physical examination, with attention to other conditions that may be causing LUTS. Digital rectal examination and urinalysis should be performed. Other testing may be considered depending on presentation of symptoms, including prostate-specific antigen, serum creatinine, urine cytology, imaging, cystourethroscopy, post-void residual, and pressure-flow studies. Many medical and surgical treatment options exist. Surgery should be reserved for patients who either have failed medical management or have complications from BPH, such as recurrent urinary tract infections, refractory urinary retention, bladder stones, or renal insufficiency as a result of obstructive uropathy.

Entities:  

Keywords:  5-alpha reductase inhibitors; adrenergic alpha-antagonists; lower urinary tract symptoms; phosphodiesterase type 5 inhibitors; transurethral resection of prostate

Mesh:

Substances:

Year:  2015        PMID: 26331999     DOI: 10.1146/annurev-med-063014-123902

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  29 in total

1.  Prostate Transition Zone Fibrosis is Associated with Clinical Progression in the MTOPS Study.

Authors:  Jill A Macoska; Kristen S Uchtmann; Glen E Leverson; Kevin T McVary; William A Ricke
Journal:  J Urol       Date:  2019-06-12       Impact factor: 7.450

2.  Green Light photoselective vaporization of the prostate: a safe and effective treatment for elderly high-risk benign prostate hyperplasia patients with gland over 80 ml.

Authors:  Jie Sun; An Shi; Zhen Tong; Chenfei Chi
Journal:  Lasers Med Sci       Date:  2018-04-28       Impact factor: 3.161

3.  Estrogen receptor β and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate.

Authors:  Wan-Fu Wu; Li Wang; Nicholas Spetsieris; Myrto Boukovala; Eleni Efstathiou; Clemens Brössner; Margaret Warner; Jan-Ake Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-30       Impact factor: 11.205

4.  Evaluation of the clinical pharmacist role in improving clinical outcomes in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.

Authors:  Mera Ababneh; Duaa Shamieh; Saddam Al Demour; Abeer Rababa'h
Journal:  Int J Clin Pharm       Date:  2019-09-06

5.  Transforming growth factor beta 1 impairs benign prostatic luminal epithelial cell monolayer barrier function.

Authors:  Feng Li; Laura E Pascal; Ke Wang; Yibin Zhou; Goundappa K Balasubramani; Katherine J O'Malley; Rajiv Dhir; Kai He; Donna Stolz; Donald B DeFranco; Naoki Yoshimura; Joel B Nelson; Tie Chong; Peng Guo; Dalin He; Zhou Wang
Journal:  Am J Clin Exp Urol       Date:  2020-02-25

6.  A two-week, double-blind, placebo-controlled trial of Viola odorata, Echium amoenum and Physalis alkekengi mixture in symptomatic benign prostate hyperplasia (BPH) men.

Authors:  Fatemeh Beiraghdar; Behzad Einollahi; Alireza Ghadyani; Yunes Panahi; Abbas Hadjiakhoondi; Mahdi Vazirian; Ali Salarytabar; Behrad Darvishi
Journal:  Pharm Biol       Date:  2017-12       Impact factor: 3.503

7.  Efficacy and tolerability of Roystonea regia lipid extract (D-004) and terazosin in men with symptomatic benign prostatic hyperplasia: a 6-month study.

Authors:  Raúl Guzmán; Julio C Fernández; Manuel Pedroso; Lilia Fernández; José Illnait; Sarahí Mendoza; Ana T Quiala; Zunilda Rodríguez; Jilma Mena; Aylim Rodíguez; Marbelis Campos; Carlos Sánchez; Yanet Alvarez; Gladys Jiménez
Journal:  Ther Adv Urol       Date:  2019-06-11

8.  Genome-wide association study identifies a role for the progesterone receptor in benign prostatic hyperplasia risk.

Authors:  Weiqiang Li; Robert J Klein
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-11-20       Impact factor: 5.554

9.  Retrospective analysis of the changes in the surgical treatment of benign prostatic hyperplasia during an 11-year period: a single-center experience.

Authors:  Zhu-Feng Peng; Jing Zhou; Pan Song; Lu-Chen Yang; Bo Yang; Zheng-Ju Ren; Lin-Chun Wang; Qiang Wei; Qiang Dong
Journal:  Asian J Androl       Date:  2021 May-Jun       Impact factor: 3.285

10.  Holmium laser enucleation of the prostate: efficacy, safety and preoperative management in patients presenting with anticoagulation therapy.

Authors:  Marina Deuker; Jessica Rührup; Pierre I Karakiewicz; Maria Welte; Luis A Kluth; Severine Banek; Frederik C Roos; Philipp Mandel; Felix K-H Chun; Andreas Becker
Journal:  World J Urol       Date:  2020-06-02       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.